| | | |   | | | | By Ed Silverman Gene J. Puskar/AP "If they don’t come up with a deadline," said Matt Wellington of PIRG, "... then it’s just wishful thinking.” Read More | | By Jason Mast Chantal Heijnen for STAT The interest is in Tmunity's leukemia and lymphoma programs, as well as technology that could speed up CAR-T manufacturing. Read More | | By Adam Feuerstein Hyacinth Empinado/STAT This list of the year's worst biopharma CEOs is about holding people and an industry accountable, Adam Feuerstein writes. Read More | | Sponsored Insight by Regeneron Is boldness the solution to R&D challenges with bispecific antibodies? Despite their inherent challenges, bispecific antibodies (bsAbs) hold promise in improving the future of cancer care. T cell manipulation via bsAbs creates room for flexibility in immunotherapy research, with the ability to be studied individually as monotherapy or in combination with other oncologic treatments. Regeneron has spent over a decade researching bispecific antibodies, following the science to gain an understanding of the bsAbs landscape to utilize them in emerging research in oncology. Learn more. | | By John Wilkerson Adobe A fracas over the Alzheimer’s drug Aduhelm could result in new power for the FDA. But pharma managed to block certain provisions. Read More | | By Nicholas Florko Andrew Harnik/AP The stinging review, which was ordered by FDA Commissioner Robert Califf in July, was conducted by the independent Reagan-Udall Foundation. Read More | |
No comments